Lucira Health to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
Lucira Health, a medical technology company, will participate in the Gilmartin Group Emerging Growth Company Showcase on August 31, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lucira Health, a medical technology company, will participate in the Gilmartin Group Emerging Growth Company Showcase on August 31, 2022. The virtual presentation is scheduled for 4:30 pm ET and will be accessible via the company's website. Lucira focuses on developing innovative infectious disease tests aimed at providing lab-quality diagnostics.
Details
News Market Reaction – LHDX
The recorded move for LHDX in the trading session of this news was +0.52%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will participate in the Gilmartin Group Emerging Growth Company Showcase on August 31st, 2022.
Lucira’s management is scheduled to present virtually at the Inaugural Gilmartin Group Emerging Growth Company Showcase on Wednesday, August 31st, 2022, at 4:30 pm ET. A live and archived webcast of the event can be accessed through the Events and Presentations page of the Lucira website.
Those parties interested in registering for the Gilmartin Group Emerging Growth Company Showcase may do so by following this link.
About Lucira Health
Lucira is a medical technology company focused on the development and commercialization of innovative infectious disease tests to make lab-quality diagnostics more accessible. Lucira designed its test platform to provide accurate, reliable, PCR-quality test results anywhere and at any time. Beyond its already commercialized COVID-19 and COVID-19 & Flu Tests, Lucira is working on new diagnostic tests for respiratory infections and other categories including women’s health and sexually transmitted infections (STIs). For more information, visit www.lucirahealth.com.
Investor Contact
Greg Chodaczek
Investorrelations@lucirahealth.com
332-895-3230
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.